Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Glioblastoma Institute
Tumor Boards
Colleague Insights
Living Resources
Conferences
Video Expert Opinion
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Brain Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Brain Cancer

Expert Opinion / Cases · March 01, 2022

60-Year-Old Male With Right Parietal Glioblastoma and KPS 80

Written by
Martin C. Tom MD

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Martin Tom MD

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Matthew Smith-Cohn

    Mar 04, 2022

    It is unclear if it would be effective but a few cases in the literature. If no clinical trial option, then it could be considered. Hyperphosphatemia could be an issue to manage. There is data on the use of Erdafitinib (Https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506218/) (but unclear efficacy in that paper) and Anlotinib (although in orphan drug in the states) (Https://theoncologist.onlinelibrary.wiley.com/doi/10.1002/onco.13530). Infigratinib is being evaluated in the phase 0 trial at the Ivy brain tumor center in Arizona for glioblastoma.

  • Rashida Karmali

    Mar 04, 2022

    J. Clinical Oncology 36: 1702-1709 (2018)

  • maria arriaga

    Mar 06, 2022

    What about arguing EGFR..?

  • May 15, 2024

    Pending Moderator approval.
    Delete

Further Reading

Recently Updated